ProfitabilityThis table compares MorphoSys and Evelo Biosciences’ net margins, return on equity and return on assets. Comparatively, Evelo Biosciences has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, 0.3% of Evelo Biosciences shares are owned by institutional investors. Comparatively, 1.0% of Evelo Biosciences shares are owned by insiders. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.